Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the main antigen in all approved COVID-19 vaccines and is also the only target for monoclonal antibody (mAb) therapies. Immune responses to other viral antigens are generated after SARS-CoV-2 infection, but their contribution to the antiviral response remains unclear. Here, we interrogated whether nucleocapsid-specific antibodies can improve protection against SARS-CoV-2. We first immunized mice with a nucleocapsid-based vaccine and then transferred sera from these mice into naive mice, followed by challenge with SARS-CoV-2. We show that mice that received nucleocapsid-specific sera or a nucleocapsid-specific mAb exhibited enhanced control of SARS-CoV-2. Nucleocapsid-specific antibodies elicited NK-mediated, antibody-dependent cellular cytotoxicity (ADCC) against infected cells. To our knowledge, these findings provide the first demonstration in the coronavirus literature that antibody responses specific to the nucleocapsid protein can improve viral clearance, providing a rationale for the clinical evaluation of nucleocapsid-based mAb therapies to treat COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
The Journal of clinical investigation - 132(2022), 23 vom: 01. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dangi, Tanushree [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.12.2022 Date Revised 14.06.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1172/JCI162282 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347346855 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347346855 | ||
| 003 | DE-627 | ||
| 005 | 20231226033616.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/JCI162282 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347346855 | ||
| 035 | |a (NLM)36219482 | ||
| 035 | |a (PII)e162282 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dangi, Tanushree |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.12.2022 | ||
| 500 | |a Date Revised 14.06.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the main antigen in all approved COVID-19 vaccines and is also the only target for monoclonal antibody (mAb) therapies. Immune responses to other viral antigens are generated after SARS-CoV-2 infection, but their contribution to the antiviral response remains unclear. Here, we interrogated whether nucleocapsid-specific antibodies can improve protection against SARS-CoV-2. We first immunized mice with a nucleocapsid-based vaccine and then transferred sera from these mice into naive mice, followed by challenge with SARS-CoV-2. We show that mice that received nucleocapsid-specific sera or a nucleocapsid-specific mAb exhibited enhanced control of SARS-CoV-2. Nucleocapsid-specific antibodies elicited NK-mediated, antibody-dependent cellular cytotoxicity (ADCC) against infected cells. To our knowledge, these findings provide the first demonstration in the coronavirus literature that antibody responses specific to the nucleocapsid protein can improve viral clearance, providing a rationale for the clinical evaluation of nucleocapsid-based mAb therapies to treat COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Adaptive immunity | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Immunology | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Sanchez, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Class, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Richner, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Visvabharathy, Lavanya |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Young Rock |e verfasserin |4 aut | |
| 700 | 1 | |a Bentley, Kirsten |e verfasserin |4 aut | |
| 700 | 1 | |a Stanton, Richard J |e verfasserin |4 aut | |
| 700 | 1 | |a Koralnik, Igor J |e verfasserin |4 aut | |
| 700 | 1 | |a Richner, Justin M |e verfasserin |4 aut | |
| 700 | 1 | |a Penaloza-MacMaster, Pablo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical investigation |d 1924 |g 132(2022), 23 vom: 01. Dez. |w (DE-627)NLM000005487 |x 1558-8238 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2022 |g number:23 |g day:01 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/JCI162282 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2022 |e 23 |b 01 |c 12 | ||